FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.

(2021) Ghassan K. Abou-Alfa et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Pathology of Urothelial Carcinoma

(2021) Antonio Lopez-Beltran et al.   HUMAN PATHOLOGY

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice

(2021) Anuhya Kommalapati et al.   Cancers

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

(2020) Tanios S Bekaii-Saab et al.   Future Oncology

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

(2020) Melanie A. Krook et al.   BRITISH JOURNAL OF CANCER

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

(2020) Ian M. Silverman et al.   Cancer Discovery

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

(2019) Rastilav Bahleda et al.   CLINICAL CANCER RESEARCH

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

(2019) Francesco Facchinetti et al.   CLINICAL CANCER RESEARCH

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

(2018) S Verstovsek et al.   ANNALS OF ONCOLOGY

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

900PInterim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

(2018) A Necchi et al.   ANNALS OF ONCOLOGY

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

(2018) Vincenzo Mazzaferro et al.   BRITISH JOURNAL OF CANCER

Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

(2016) Lipika Goyal et al.   Cancer Discovery

Targeting FGFR Signaling in Cancer

(2015) M. Touat et al.   CLINICAL CANCER RESEARCH

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

(2015) Chiara Degirolamo et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer

(2012) A. N. Brooks et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER